GlassScriptPhysician profile
Abby L Sipe
NPI 1528725793
$46,565.69
in general payments reported to CMS, 2019-2025
37 companies · $15K in 2025
The $15K reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $98.81 · 2022: $3,062 · 2023: $8,319 · 2024: $20K · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $18K · Consulting Fee: $14K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,984 · Travel and Lodging: $2,376 · Education: $520.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $17,982.35 |
| Consulting Fee | $13,542.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,984.00 |
| Travel and Lodging | $2,375.81 |
| Education | $520.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $14,729.05 | 2022-2025 | |
| Incyte Corporation | $5,531.15 | 2022-2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $3,906.24 | 2022-2025 | Sotyktu |
| Eli Lilly and Company | $2,708.86 | 2025 | Ebglyss |
| Janssen Biotech, INC. | $2,662.41 | 2022-2025 | Tremfya |
| Lilly USA, LLC | $2,329.67 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Verrica Pharmaceuticals INC. | $2,111.87 | 2023-2025 | Ycanth |
| Lumenis Be INC | $1,754.43 | 2023 | M22 |
| Arcutis Biotherapeutics, INC. | $1,568.20 | 2023-2025 | Zoryve |
| Ucb, INC. | $1,552.25 | 2023-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $1,498.50 | 2022-2025 | |
| Galderma Laboratories, L.P. | $1,102.48 | 2022-2025 | Aklief, Epsolay, Oracea |
| Genzyme Corporation | $1,083.35 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,075.44 | 2022-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $607.39 | 2022-2025 | Absorica Ld, Winlevi, Ilumya |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $428.14 | 2022-2023 | Tremfya |
| Boehringer Ingelheim Pharmaceuticals, INC. | $313.56 | 2022-2025 | Spevigo |
| Leo Pharma INC. | $294.45 | 2023-2025 | Adbry, Anzupgo |
| Amgen INC. | $248.01 | 2022-2025 | Otezla, Otezla |
| Organon LLC | $149.93 | 2025 | Vtama |
| Revance Therapeutics, INC. | $147.53 | 2025 | Daxxify |
| Pfizer INC. | $137.38 | 2022-2025 | |
| Dermavant Sciences, INC. | $98.92 | 2023-2024 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $89.35 | 2023-2024 | Cabtreo, Siliq |
| Mayne Pharma Commercial LLC | $78.12 | 2025 | |
| Regeneron Pharmaceuticals, INC. | $61.90 | 2023 | Dupixent |
| Mallinckrodt Hospital Products INC. | $56.91 | 2025 | Acthar |
| Almirall LLC | $34.36 | 2022-2023 | Seysara |
| Fresenius Kabi USA, LLC | $31.63 | 2023-2024 | Idacio |
| Organogenesis INC. | $29.72 | 2024 | |
| Medimetriks Pharmaceuticals, INC. | $24.22 | 2024 | Clindacin Etz |
| Sandoz INC. | $23.65 | 2024 | Hyrimoz |
| Lnhc, INC | $23.03 | 2025 | Zelsuvmi |
| Krystal Biotech INC | $23.00 | 2025 | Vyjuvek |
| Biofrontera INC. | $19.50 | 2023 | Ameluz, Xepi, Bf-Rhodoled |
| Allergan, INC. | $16.54 | 2022 | |
| Botanix Sb INC | $14.55 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abby Sipe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.